Faron Pharmaceuticals Oy - Finland-based biopharmaceutical company with a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy - Says pretax loss widened for the first half ended June 30 to EUR7.3 million from EUR6.4 million a year prior. Says general and administrative expenses widened to EUR2.4 million from EUR1.4 million a year before. Notes that despite the global pandemic and the consequent restrictions it was able to continue to operate almost normally and the development of its clinical trials proceeded as planned.
Chief Executive Markku Jalkanen said: "As the scientific community has rallied in 2020 to identify therapies for Covid-19 patients, I am proud that Faron has been able to support two global initiatives and a planned US trial, to investigate the potential of Traumakine for the treatment of ARDS and Covid-19."
Current stock price: 390.00 pence
Year-to-date change: up 49%
By Greg Roxburgh; email@example.com
Copyright 2020 Alliance News Limited. All Rights Reserved.